|
Post by sla55 on Jul 11, 2019 15:18:38 GMT -5
investors.mannkindcorp.com/news-releases/news-release-details/mannkind-expands-commercial-scale-manufacturing-capabilitiesMannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency MoleculesWESTLAKE VILLAGE, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation(Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility. This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization. “This expansion will allow us to utilize more fully the capacity of our world class, FDA-approved manufacturing facility for dry powder inhalation products. We are also pursuing opportunities to utilize our lyophilization capacity to fulfill the needs of our industry and drug development partners," stated Joe Kocinsky, Chief Technology Officer of MannKind.
|
|
|
Post by sportsrancho on Jul 11, 2019 15:20:07 GMT -5
|
|
|
Post by mango on Jul 11, 2019 15:31:12 GMT -5
Nice. Sounds good to me.
|
|
|
Post by hellodolly on Jul 11, 2019 15:40:49 GMT -5
investors.mannkindcorp.com/news-releases/news-release-details/mannkind-expands-commercial-scale-manufacturing-capabilitiesMannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency MoleculesWESTLAKE VILLAGE, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation(Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility. This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization. “This expansion will allow us to utilize more fully the capacity of our world class, FDA-approved manufacturing facility for dry powder inhalation products. We are also pursuing opportunities to utilize our lyophilization capacity to fulfill the needs of our industry and drug development partners," stated Joe Kocinsky, Chief Technology Officer of MannKind. Does this tie in to their next milestone in any way with UTHR? I thought I heard Mike say something about them having to accomplish this in order to take their next step???
|
|
|
Post by sportsrancho on Jul 11, 2019 15:45:45 GMT -5
|
|
|
Post by dg1111 on Jul 11, 2019 15:51:15 GMT -5
Is this statement signaling movement on an epinephrine partnership?
"This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships."
|
|
|
Post by boca1girl on Jul 11, 2019 15:52:54 GMT -5
What Found it interesting that they named epinephrine as an example in the article. I hope that means they found a partner for Epi-T.
|
|
|
Post by rtmd on Jul 11, 2019 15:58:06 GMT -5
For some reason, I'm feeling smoke getting in my eyes. This is the kind of "news" I expect right before a company announces a secondary. They need more money for this "expansion," yadda-yadda.
|
|
|
Post by sportsrancho on Jul 11, 2019 15:59:32 GMT -5
What Found it interesting that they named epinephrine as an example in the article. I hope that means they found a partner for Epi-T. 👍🏻
|
|
|
Post by mytakeonit on Jul 11, 2019 16:07:25 GMT -5
And sports is sitting pretty with her new MNKD shares !!! She doesn't have to worry about the little price differential.
But, that's mytakeonit
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 11, 2019 16:24:31 GMT -5
For some reason, I'm feeling smoke getting in my eyes. This is the kind of "news" I expect right before a company announces a secondary. They need more money for this "expansion," yadda-yadda. I doubt it....They don't have that many Auth Shares and at this price would not be smart. I'm expecting more partnerships and maybe this PR is giving new developmental partners the green light.
|
|
|
Post by apidistra on Jul 11, 2019 16:27:12 GMT -5
Who expands capacity without a pipeline? I think we must have a pipeline!
|
|
|
Post by theshiv on Jul 11, 2019 16:29:29 GMT -5
This announcement is promising for the future. It also suggests clearly management is working every day to advance the company, despite the noise from the gallery.
|
|
|
Post by sportsrancho on Jul 11, 2019 16:37:03 GMT -5
|
|
|
Post by sportsrancho on Jul 11, 2019 16:38:42 GMT -5
So I’m guessing we have a partner for Epi. That it’s not the secret molecule, that that one resembles Cialis. And if we don’t have a partner then our sales reps can sell Epi.
|
|